Collectively, the above preclinical evidence and clinical studies have paved the way for additional clinical trials of ibrutinib and acalabrutinib as well as other BTK inhibitors for the treatment of IgE-dependent anaphylaxis, food allergy, drug allergy, asthma, CSU and other difficult-to-treat allergic diseases. Here, BTK is linked to allergic disease.